STOPNET

Protocol Title

A randomised study of cessation of somatostatin analogues after Peptide Receptor Radionuclide Therapy in Mid, Hind-Gut and Pancreatic Neuroendocrine tumours (STOPNET)

Purpose of the Study

Neuroendocrine tumours (NETs) are slow growing cancers, which commonly present as metastatic incurable disease. Some neuroendocrine tumours, termed functional NETs, overproduce hormones which result in a variety of symptoms. However, approximately 75% of NETs are considered non-functional meaning that they do not result in hormone overproduction. The main treatment for both functional and non-functional NETs is somatostatin analogues (SSA, a type of inhibitory hormone). These drugs slow tumour growth and reduce hormone production. Over time, the majority of patients will experience tumour growth despite treatment with SSA therapy. When this occurs, the addition of Peptide Receptor Radionuclide Therapy (PRRT, a type of targeted radiotherapy) in combination with ongoing SSA therapy is given. However, it is not known if continuing SSA therapy after commencement of PRRT is beneficial or not.

The aim of this randomised study is to compare the outcomes (progression free survival, cost effectiveness, and overall quality of life) of patients with well or moderately differentiated mid, hindgut or pancreatic neuroendocrine tumours, in whom SSA therapy is continued or ceased prior to PRRT initiation.

Contact Email

GCT_STOPNET_Mailbox@gicancer.org.au

DETAILED INFORMATION AVAILABLE

More detailed information available online at ClinicalTrials.gov please click here.

STUDY CHAIRS

A/Prof Matthew Burge
A/Prof David Wyld
A/Prof David Pattison

Funding

GI Cancer Trials (formerly AGITG) philanthropic funding
2023 Tour De Cure Grant
2022 MRFF Clinical Trial Activity Grant

Patients Recruited

Click here to access the table and view recruitment data on all GCT open trials:

Open Trial Recruitment Table